Abstract: The proposed morphable sheet structure comprises a succession of adjacent flexible elongated rods (10) laterally connected to each other defining a sheet structure (1), each rod (10) defining a longitudinal axis (A); wherein the rods (10) are grouped in pairs, each pair of adjacent rods (10) are connected to each other through a first connector (11) tightly connected to a second connector (12) complementary with the first connector (11), being the first connector (11) part of one rod (10) of said pair of adjacent rods (10) and being the second connector (12) part of the other rod (10) of said pair of adjacent rods (10); being the first connector (11) and the second connector (12) slidably movable to each other in the direction of the longitudinal axis (A); the first connector (11) and/or the second connector (12) extending along the entire longitude of the rod (10).

Abstract: The invention relates to functional nucleic acid molecules comprising a target determinant sequence and a regulatory sequence wherein the functional nucleic acid molecule comprises one or more chemical modifications, particularly for use in methods of increasing target protein synthesis efficiency.

Abstract: There is disclosed a trans-acting functional nucleic acid molecule comprising a eukaryotic target binding sequence comprising a sequence reverse complementary to a target mRNA sequence for which protein translation is to be enhanced, and a regulatory sequence comprising an internal ribosome entry site (IRES) sequence or an internal ribosome entry site (IRES) derived sequence and enhancing translation of the target mRNA sequence, wherein the regulatory sequence is located 3? of the target binding sequence.

Abstract: The proposed morphable sheet structure comprises a succession of adjacent flexible elongated rods (10) laterally connected to each other defining a sheet structure (1), each rod (10) defining a longitudinal axis (A); wherein the rods (10) are grouped in pairs, each pair of adjacent rods (10) are connected to each other through a first connector (11) tightly connected to a second connector (12) complementary with the first connector (11), being the first connector (11) part of one rod (10) of said pair of adjacent rods (10) and being the second connector (12) part of the other rod (10) of said pair of adjacent rods (10); being the first connector (11) and the second connector (12) slidably movable to each other in the direction of the longitudinal axis (A); the first connector (11) and/or the second connector (12) extending along the entire longitude of the rod (10).

Abstract: There are disclosed functional nucleic acid molecules comprising a target binding sequence comprising a sequence reverse complementary to a target mRNA sequence for which protein translation is to be enhanced; and a regulatory sequence having two-dimensional structures comprising specific stem-loop and internal loop domains and displaying translation enhancing efficiency.

Abstract: There is disclosed a trans-acting functional nucleic acid molecule comprising a eukaryotic target binding sequence comprising a sequence reverse complementary to a target mRNA sequence for which protein translation is to be enhanced, and a regulatory sequence comprising an internal ribosome entry site (IRES) sequence or an internal ribosome entry site (IRES) derived sequence and enhancing translation of the target mRNA sequence, wherein the regulatory sequence is located 3? of the target binding sequence.

Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.

Abstract: The present invention relates to the medical field, in particular to the use of natural organic polyanions, i.e. humic substances, HSs, in the treatment of neurodegenerative diseases, such as Prion disease, Alzheimer's and Parkinson's disease.

Abstract: The present invention relates to the two main categories of humic substances, humic acids and fulvic acids and their use for hindering the propagation and/or contamination with prion infectivity both in agricultural and environmental systems.

Abstract: Method for the humanization of the VII and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.

Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.

Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.

Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.

Abstract: A non-human transgenic animal that is transgenic for an antibody or fragments thereof and having a phenotype reminiscent of human pathology. The human pathology includes neurodegenerative syndromes, muscular atrophy/dystrophy and immune disorders. The animals may be used in a method for early diagnosis of neurodegenerative diseases. The method includes monitoring the occurrence of the tau hyperphosphorylation and/or amyloid deposition in the back or lower limb skeletal muscle sample of a subject. Cells are derivable from the non-human transgenic animal and secreting the transgenic antibody. The cells are used for the selection of molecules pharmacologically effective in neurodegenerative and/or muscular pathologies and/or immune disorders.

Abstract: Muteins of the Ser-Cys-Asn-Thr-Ala-Thr-Cys sequence from the N-terminal 1-7 fragment of the CGRP peptide, possessing an enhancing action on the activation of neuronal nicotinic receptors, their pharmaceutical compositions containing the same and their use for the potential therapy of neurological diseases are described.